Nombre de documents


CV de david smadja

Article dans une revue6 documents

  • David Smadja. Bone marrow Very small embryonic-like stem cells: New generation of autologous cell therapy soon ready for prime time?. Stem Cell Reviews and Reports, Humana Press, 2017, [Epub ahead of print]. <10.1007/s12015-017-9718-4 >. <inserm-01446765>
  • Maria Bruzelius, J. Iglesias, Mun-Gwan Hong, Laura Sanchez-Rivera, Beata Gyorgy, et al.. PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study.. Blood, American Society of Hematology, 2016, 128 (23), pp.e59-e66. <hal-01479709>
  • Marine Germain, Daniel I Chasman, Hugoline De Haan, Weihong Tang, Sara Lindström, et al.. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism.. American Journal of Human Genetics, Elsevier (Cell Press), 2015, 96 (4), pp.532-42. <10.1016/j.ajhg.2015.01.019>. <hal-01259946>
  • Clément D’audigier, Benoit Gautier, Alexis Yon, Jean-Meidi Alili, Coralie L. Guérin, et al.. Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential. Angiogenesis, Springer Verlag, 2014, 17 (3), p. 603-616. <10.​1007/​s10456-013-9413-2>. <hal-01300965>
  • David Smadja. [Therapeutics. New anticoagulants: stop the controversy!].. Revue du Praticien (La), J B Bailliere et Fils, 2013, 63 (8), pp.1044-7. <inserm-00916701>
  • David Smadja, Marie-Anne Loriot, Lucia Hindorff, Lucille Mellottee, Pascale Gaussem, et al.. No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease.. Thrombosis and Haemostasis, Schattauer, 2008, 99 (5), pp.970-972. <10.1160/TH07-12-0742>. <inserm-00277129>